- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute | Strategic Alliance Partners
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Latest from Dana-Farber Cancer Institute
Novel Studies Seek to Optimize HER2+ Breast Cancer Management
August 07, 2024
Article
Sara M. Tolaney, MD, MPH, discusses the use of ADCs in HER2-positive breast cancer and ongoing research in this patient population.
Dr Tolaney on Data With Checkpoint Inhibitor Combinations in Metastatic TNBC
August 07, 2024
Video
Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.
Dana-Farber's Edward Chouchani selected as a Howard Hughes Medical Institute Investigator
August 07, 2024
Article
Edward Chouchani, PhD, of Dana-Farber Cancer Institute, has been named a Howard Hughes Medical Institute Investigator.
Emerging HER2+ Breast Cancer Research Uses Innovative Combinations of Standard Agents
August 06, 2024
Article
Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.
Residual Cancer Burden May Prognosticate Outcomes With Neoadjuvant Therapy in Prostate Cancer
August 06, 2024
Article
Praful Ravi, MB, BChir, MRCP, discusses an analysis measuring residual cancer burden in localized prostate cancer after neoadjuvant therapy and surgery.
Dr Florez on Addressing Key Gaps in Lung Cancer Care
August 05, 2024
Video
Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.
Dr Rotow on Challenges With Targeting CNS Metastases in Lung Cancer
August 01, 2024
Video
Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.
First-Line Avelumab Maintenance Extends OS in Advanced Urothelial Carcinoma With Low Tumor Burden
July 30, 2024
Article
First-line avelumab maintenance demonstrated efficacy and manageable toxicity in patients with low tumor burden advanced urothelial carcinoma.
Tolaney Details IHC Testing Considerations for HER2-Low TNBC and Data on ADCs
July 29, 2024
Article
Sara M. Tolaney, MD, MPH, shares biopsy considerations when determining HER2-low status for patients with TNBC and details data within the TNBC landscape.
Dr Ravi on the Potential Use of RCB to Inform Neoadjuvant Strategies in High-Risk Prostate Cancer
July 29, 2024
Video
Praful K. Ravi, MB, BChir, MRCP, discusses the use of residual cancer burden to guide intensified neoadjuvant treatment in high-risk prostate cancer.
Tarantino Talks Limitations in HER2-Low Breast Cancer Management, Key Advancements in HER2+/TNBC
July 28, 2024
Article
Paolo Tarantino, MD, discusses current treatment landscapes and looks to the future in HER2-low breast cancer, HER2-positive breast cancer, and TNBC.
From Targetless to Targetable, Breakthroughs Push Forward in TNBC Treatment Landscape
July 26, 2024
Article
Sara M. Tolaney, MD, MPH, discusses the transformation of treatments for patients with triple-negative breast cancer.
Changes in HER2+ Breast Cancer May Include Tailored Therapy With pCR, Use of T-DXd
July 26, 2024
Article
Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.
Dr Sands on the Evolving Role of ADCs in SCLC Management
July 25, 2024
Video
Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.
Dr Morgans on the Relationship Between PSA Levels and Radiographic Progression in nmCRPC
July 25, 2024
Video
Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
July 25, 2024
Article
Lajos Pusztai, MD, DPhil, discusses molecular residual disease monitoring in early-stage breast cancer.
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
July 25, 2024
Video
Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.
Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer
July 24, 2024
Article
Paolo Tarantino, MD, discusses questions about the optimal sequencing of antibody-drug conjugates in endocrine-refractory, HR-positive breast cancer.
Dr Tolaney on the Development of Mutation-Selective PI3K Inhibitors in Breast Cancer
July 24, 2024
Video
Sara M. Tolaney, MD, MPH, discusses the ongoing development of mutation-selective PI3K inhibitors in PI3K-mutant metastatic breast cancer.
Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line
July 24, 2024
Article
Adrienne G. Waks, MD, details her approach to treatment sequencing in metastatic HER2-positive disease and the potential role of T-DXd in the first line.